menu
    • menu
    [{"orgOrder":0,"company":"ScaleReady","sponsor":"TC BioPharm","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Cell and Gene therapy","year":"2024","type":"Funding","leadProduct":"Cyclophosphamide","moa":"","graph1":"Technology","graph2":"Approved","graph3":"ScaleReady","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Technology","amount2New":0.10000000000000001,"dosageForm":"","sponsorNew":"ScaleReady \/ ScaleReady","highestDevelopmentStatusID":"12","companyTruncated":"ScaleReady \/ ScaleReady"},{"orgOrder":0,"company":"ScaleReady","sponsor":"OverT Bio","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Funding","leadProduct":"Cell-based Therapy","moa":"","graph1":"Technology","graph2":"Approved","graph3":"ScaleReady","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Technology","amount2New":0.10000000000000001,"dosageForm":"","sponsorNew":"ScaleReady \/ ScaleReady","highestDevelopmentStatusID":"12","companyTruncated":"ScaleReady \/ ScaleReady"}]

    Find Clinical Drug Pipeline Developments & Deals by ScaleReady

    Menu

    ScaleReady

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            ScaleReady

                            U.S.A arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed

                            ScaleReady

                            U.S.A arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Cell-based Therapy

                            Therapeutic Area : Oncology

                            Study Phase : Discovery Platform

                            Recipient : OverT Bio

                            Deal Size : $0.1 million

                            Deal Type : Funding

                            DEALS_DEV arrow-down

                            OverT Bio Receives $120K G-Rex® Grant to Propel Solid Tumor Cell Therapy Advancements

                            Details : The grant will support OverT Bio’s ongoing development efforts leading to next generation cell therapies for solid tumors, based on innovative data-driven discovery platforms OverTarget and OverTCR.

                            Brand Name : Undisclosed

                            Molecule Type : Cell and Gene therapy

                            Upfront Cash : Undisclosed

                            November 22, 2024

                            Lead Product(s) : Cell-based Therapy

                            Therapeutic Area : Oncology

                            Highest Development Status : Discovery Platform

                            Recipient : OverT Bio

                            Deal Size : $0.1 million

                            Deal Type : Funding

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            ScaleReady

                            U.S.A arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed

                            ScaleReady

                            U.S.A arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : OmnImmune,Cyclophosphamide,Fludarabine Phosphate

                            Therapeutic Area : Oncology

                            Study Phase : Phase II

                            Recipient : TC BioPharm

                            Deal Size : $0.2 million

                            Deal Type : Funding

                            DEALS_DEV arrow-down

                            TCBP Awarded Non-Dilutive Funding, ScaleReady's G-Rex® Grant

                            Details : The grant will support TCB008 manufacturing process optimizations. OmnImmune is an allogeneic unmodified cell therapy for the treatment of patients suffering from relapse/refractory AML.

                            Brand Name : TCB008

                            Molecule Type : Cell and Gene therapy

                            Upfront Cash : Undisclosed

                            November 12, 2024

                            Lead Product(s) : OmnImmune,Cyclophosphamide,Fludarabine Phosphate

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase II

                            Recipient : TC BioPharm

                            Deal Size : $0.2 million

                            Deal Type : Funding

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth